ROLE OF TRANEXAMIC ACID IN REDUCING BLOOD LOSS IN VAGINAL DELIVERY
- Conditions
- Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium
- Registration Number
- CTRI/2021/02/031360
- Lead Sponsor
- Gamidi Anusha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Age > 19 years and < 40 years
2)Spontaneous vaginal delivery
3)Induced vaginal delivery
4)Assisted vaginal delivery
5)Term > 35 weeks of gestation
6)Singleton pregnancy
1)History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris,myocardial infarction, stroke) thrombosis
2) History of epilepsy or seizure
3) Any known cardiovascular, renal, or liver disorders
4)History of Autoimmune disease
5) History of Sickle cell disease
6) History of Severe hemorrhagic disease
7) Placenta previa
8)Abnormally invasive placenta (placenta accreta/increta/percreta)
9) Abruptio placentae
10) Eclampsia, HELLP syndrome
11) Multiple pregnancy
12) In utero fetal death
13) Administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery
14)PROMâ??patients referred from periphery with PROM were excluded as the chances of chorioamnionitis were more due to repeated internal examinations
15)Prolonged and obstructed labour
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Injection Tranexamic acid administration along with oxytocin can reduce obstetric blood lossTimepoint: 24 months
- Secondary Outcome Measures
Name Time Method Injection tranexamic acid administration along with oxytocin can reduce obsetric blood lossTimepoint: 24 months